Dermata Posts Q2 Loss, Targets August 25 Debut for First Skincare Line
DRMA sits 16% above its 52-week low of $0.951 on light trading volume (0.3× avg).
Summary
Dermata Therapeutics reported Q2 2026 results with a $2.97M net loss and $4.4M in cash, providing runway into Q4 2026. The company confirmed its first product launch, Tome Foundational Treatment, for August 25, 2026.
Key Events · Earnings and Guidance · DRMA
-
Q2 2026 Financial Results
Net loss of $2.97 million on operating expenses of $3.01 million. Cash and equivalents stood at $4.4 million as of June 30, 2026, down from $7.5 million at year-end 2025.
-
Cash Runway into Q4 2026
Management expects current cash to fund operations into the fourth quarter of 2026, implying a need for additional capital before year-end.
-
First Product Launch Confirmed
Tome Foundational Treatment, a direct-to-consumer skincare product, will launch on August 25, 2026, representing the company's transition to a commercial-stage entity.
-
ATM Financing Proceeds
The company raised approximately $1.9 million through its at-the-market offering program during the first half of 2026, partially offsetting cash used in operations.
Analysis · DRMA · Life Sciences
Dermata disclosed its Q2 2026 financials, revealing a net loss of $2.97 million and cash of $4.4 million, which funds operations only into Q4 2026. The company also confirmed the August 25 launch date for Tome Foundational Treatment, its first commercial product, marking a critical pivot to revenue generation. While the launch is a positive milestone, the tight cash runway and ongoing losses underscore the urgency of commercial success.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRMA was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.95 to $6.58. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.